Home>Topics>Companies>Biogen Idec

Biogen Idec

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. Cramer's Mad Money: The 4 Horsemen Trample Big Pharma (7/23/14)

    Headlines

    Thu, 24 Jul 2014

    Regeneron (NASDAQ: REGN ), Gilead (NASDAQ: GILD ), Biogen Idec (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ), GlaxoSmithKline ..... Horsemen": Regeneron ( REGN ), Gilead ( GILD ), Biogen Idec ( BIIB ) and Celgene ( CELG ). Sales of these four surpass

  2. UPDATE 4- Biogen revenue trounces forecast as MS drug sales surge

    Headlines

    Wed, 23 Jul 2014

    July 23 (Reuters) - Biogen Idec Inc reported blowout quarterly results and raised its full-year forecast on Wednesday on surging sales of its new Tecfidera oral treatment for multiple sclerosis,...

  3. Biogen's Results Cure Some Pain

    Headlines

    Wed, 23 Jul 2014

    comments sent the Biotech Index and bellwethers like Biogen (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ), and Gilead (NASDAQ ..... biotech names, not the large cap names. Clearly, Biogen Idec 's "valuation" is less of a concern given the

  4. Biogen Idec's ( BIIB ) CEO George Scangos on Q2 2014 Results - Earnings Call Transcript

    Headlines

    Wed, 23 Jul 2014

    Biogen Idec Inc . (NASDAQ: BIIB ) Q2 2014 Earnings Conference Call July 23, 2014 09:00 ET Executives ..... today. At this time, I would like to welcome everyone to the Biogen Idec Q2 2014 Earnings Conference Call. All lines have been placed

  5. Biogen Idec Beats And Raises: Reassessing Its Prospects

    Headlines

    Wed, 23 Jul 2014

    lines and pipeline of Biogen Idec (NASDAQ: BIIB ). This is a company ..... too low here and that BIIB is probably headed for ..... ground. Introduction : Biogen Idec reported blowout numbers today: Biogen Idec Inc . today reported second

  6. EC clears Plegridy

    Headlines

    Wed, 23 Jul 2014

    The European Commission approves Biogen Idec 's ( BIIB +11.2% ) Plegridy ( peginterferon beta-1a ) as a treatment ..... subcutaneous injection using a prefilled syringe. Plegridy is Biogen 's fifth product offering for MS. Post your comment!

  7. BRIEF- Biogen says tax inversions are not an adequate rationale for mergers

    Headlines

    Wed, 23 Jul 2014

    July 23 (Reuters) - Biogen Idec Inc : * Says in an investor conference call that company does not think tax inversions are an adequate rationale for business

  8. BRIEF- Biogen Idec says EU has approved its Plegridy drug for multiple sclerosis

    Headlines

    Wed, 23 Jul 2014

    July 23 (Reuters) - Biogen Idec Inc : * Says EU has approved its Plegridy drug for multiple sclerosis. Medicine is a pegylated form of interferon given by injection once every two weeks.

  9. New Morningstar Analyst Report for Biogen Idec Inc

    Stock Reports

    Wed, 23 Jul 2014

    Tecfidera's growth trajectory. Biogen leads the $15 billion ..... the merger, served as Biogen Idec 's CEO and president ..... prioritization, from which Biogen Idec could benefit. In addition ..... potential acquirers. Biogen Idec discovers, develops

  10. Biogen's Strong 2Q Has Long-Term Impact on Value of MS Franchise; Significantly Raising Our FV

    Commentary

    Wed, 23 Jul 2014

    Biogen Idec reported second-quarter results that were ..... That said, we believe that investors in Biogen at recent prices assume a strong hemophilia ..... competitors), and a high success rate for Biogen 's novel drug candidates (many of which

« Prev12345Next »
Content Partners